Detected ·
Fore Biotherapeutics
$67.5M—
Fore Biotherapeutics closed a $67.5M Series D-2 Extension financing (bringing total Series D-2 to $110M), co-led by SR One, Medicxi, and SymBiosis, to advance plixorafenib, a first-in-class BRAF inhibitor for hard-to-treat cancers.
- Website
- fore.bio
- Amount
- $67 500 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-07 16:24:49 UTC
- Signal ID
- d893d2f1-9283-487f-a387-a26d596d8fd7
As the API returns it
{
"id": "d893d2f1-9283-487f-a387-a26d596d8fd7",
"created_at": "2026-07-07T16:24:49.723006Z",
"company_name": "Fore Biotherapeutics",
"company_website_url": "fore.bio",
"company_linkedin_url": "https://www.linkedin.com/company/forebiotherapeutics",
"event_type": "funding",
"funding_amount": 67500000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Fore Biotherapeutics closed a $67.5M Series D-2 Extension financing (bringing total Series D-2 to $110M), co-led by SR One, Medicxi, and SymBiosis, to advance plixorafenib, a first-in-class BRAF inhibitor for hard-to-treat cancers.*"
}